DT&C RRO and Matica BioLabs partner for biopharmaceutical development

DT&C RRO has signed a Memorandum of Understanding (MOU) with Matica BioLabs, a subsidiary of Cha Biotech, to provide integrated solutions for the entire lifecycle of biopharmaceutical development.

The partnership aims to combine DT&C RRO’s expertise in non-clinical and clinical trials with Matica BioLabs’ capabilities as a Contract Development and Manufacturing Organization (CDMO) specializing in cell and gene therapies (CGT).

Key areas of cooperation include connecting clients requiring both CDMO and Contract Research Organization (CRO) services, identifying joint business opportunities in advanced regenerative medicine, and facilitating technical exchanges. The collaboration is designed to support biotech ventures and pharmaceutical companies by providing a unified development strategy that spans from early-stage process development to clinical trials.